Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
PSNL 
Personalis Inc (PSNL)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
09/17/2025: PSNL (4-star) is a STRONG-BUY. BUY since 2 days. Simulated Profits (-2.39%). Updated daily EoD!
Upturn Star Rating
Above Average Performance
These Stocks/ETFs, based on Upturn Advisory, frequently surpass the market, reflecting reliable and trustworthy advice.
Number of Analysts
7 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $7.06
1 Year Target Price $7.06
| 4 | Strong Buy |
| 2 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 65.64% | Avg. Invested days 28 | Today’s Advisory Strong Buy |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 09/17/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 520.53M USD | Price to earnings Ratio - | 1Y Target Price 7.06 |
Price to earnings Ratio - | 1Y Target Price 7.06 | ||
Volume (30-day avg) 7 | Beta 1.77 | 52 Weeks Range 2.83 - 7.79 | Updated Date 09/17/2025 |
52 Weeks Range 2.83 - 7.79 | Updated Date 09/17/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.28 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -113.7% | Operating Margin (TTM) -126.75% |
Management Effectiveness
Return on Assets (TTM) -20.26% | Return on Equity (TTM) -60.26% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 395060977 | Price to Sales(TTM) 6.48 |
Enterprise Value 395060977 | Price to Sales(TTM) 6.48 | ||
Enterprise Value to Revenue 4.92 | Enterprise Value to EBITDA -0.03 | Shares Outstanding 88677104 | Shares Floating 52594365 |
Shares Outstanding 88677104 | Shares Floating 52594365 | ||
Percent Insiders 31.36 | Percent Institutions 52.26 |
Upturn AI SWOT
Personalis Inc
Company Overview
History and Background
Personalis, Inc. was founded in 2011. It focuses on advanced genomic testing and analysis services to personalize cancer treatment and accelerate drug development.
Core Business Areas
- NeXT Personalu00ae: Comprehensive genomic profiling of tumors using a combination of whole-exome sequencing and RNA sequencing, providing detailed insights into individual cancer genomes. Designed to predict drug response and resistance.
- ImmunoID NeXT Platform: A platform that provides insights into both the tumor and the immune system to facilitate personalized immunotherapy strategies.
- Pharma Services: Offers genomic services to pharmaceutical companies to support drug development, clinical trials, and companion diagnostics development.
Leadership and Structure
Personalis is led by a board of directors and an executive management team. The structure is organized around research & development, commercial operations, and corporate functions.
Top Products and Market Share
Key Offerings
- NeXT Personalu00ae: Comprehensive tumor profiling for personalized cancer treatment. While specific market share data is not publicly available, this platform competes with other comprehensive genomic profiling services from companies such as Foundation Medicine and Guardant Health. Revenue from this product is a significant portion of Personalis total revenue.
- ImmunoID NeXT Platform: Analysis of the tumor microenvironment and immune response, aiding in immunotherapy development. No specific market share data is publicly available. Key competitors include Adaptive Biotechnologies.
- Pharma Services: Genomic services for pharmaceutical drug development. This sector competes with companies like Illumina, Thermo Fisher Scientific, and Qiagen.
Market Dynamics
Industry Overview
The genomic testing market is rapidly growing due to advances in sequencing technologies, increasing demand for personalized medicine, and the expanding application of genomics in drug development.
Positioning
Personalis is positioned as a provider of comprehensive genomic profiling services, particularly focusing on immuno-oncology and personalized cancer treatment. Its competitive advantage lies in its advanced sequencing technologies and analytical capabilities.
Total Addressable Market (TAM)
The total addressable market (TAM) for cancer genomics is estimated to be in the tens of billions of dollars. Personalis is targeting a specific niche within this large market, focusing on personalized cancer treatments and immuno-oncology, aiming to capture a significant portion of the TAM.
Upturn SWOT Analysis
Strengths
- Advanced genomic profiling technology
- Focus on personalized cancer treatment
- Strong relationships with pharmaceutical companies
- Expertise in immuno-oncology
Weaknesses
- Relatively small market share compared to larger competitors
- Reliance on a limited number of customers for a significant portion of revenue
- Historically operating at a loss, dependent on future contracts for growth
Opportunities
- Expanding applications of genomics in drug development
- Increasing demand for personalized cancer treatment
- Partnerships with pharmaceutical companies
- Development of new genomic tests
Threats
- Competition from larger, more established genomic testing companies
- Pricing pressures in the genomic testing market
- Regulatory changes
- Slowdown in pharmaceutical R&D spending
Competitors and Market Share
Key Competitors
- FMI
- GH
- ILMN
- TMO
Competitive Landscape
Personalis' advantages lie in its advanced genomic profiling technology and focus on personalized cancer treatment. Disadvantages include its smaller size and market share compared to larger competitors like Foundation Medicine and Guardant Health. PSNL needs to increase their market share to show revenue growth.
Growth Trajectory and Initiatives
Historical Growth: Personalis has experienced growth in revenue as it has expanded its genomic testing services and partnerships with pharmaceutical companies. However, profitability has been a challenge.
Future Projections: Analyst projections vary, but generally expect continued revenue growth driven by increasing demand for personalized cancer treatment and genomic services for drug development.
Recent Initiatives: Recent initiatives include expanding the capabilities of its genomic testing platforms, securing new partnerships with pharmaceutical companies, and expanding its sales and marketing efforts.
Summary
Personalis is a genomic testing company focused on personalized cancer treatment and immuno-oncology. While they have advanced technology and partnerships, they face competition from larger players and have yet to achieve consistent profitability. Future success depends on expanding market share, securing key contracts, and managing operational costs. Financial Performance needs to be in positive territory and look out for competition.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company SEC Filings (10-K, 10-Q)
- Company Website
- Analyst Reports
- Industry Research Reports
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. Market share data is based on estimates and may not be precise. Financial data is subject to change. Always consult with a qualified financial advisor before making any investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Personalis Inc
Exchange NASDAQ | Headquaters Fremont, CA, United States | ||
IPO Launch date 2019-06-20 | President, CEO & Director Mr. Christopher M. Hall | ||
Sector Healthcare | Industry Diagnostics & Research | Full time employees 228 | Website https://www.personalis.com |
Full time employees 228 | Website https://www.personalis.com | ||
Personalis, Inc. develops, markets, and sells advanced cancer genomic tests and services in the United States and internationally. The company offers NeXT Personal, a tumor-informed liquid biopsy test for detection of minimal residual disease (MRD), therapy response and recurrence monitoring in solid tumor cancers; and ImmunoID NeXT, a tissue-based service that combines whole exome and whole transcriptome sequencing data with advanced analytics to provide a multi-dimensional view of the tumor and the tumor microenvironment from a single sample. It also provides NeXT Personal Dx, a tumor-informed liquid biopsy test for the detection of MRD; and NeXT Dx, a tumor profiling test that is used to help select therapy for a cancer patient and identify potential clinical trials for a patient. In addition, the company performs whole exome sequencing of cancer tissue and matched blood samples for diagnostic companies as an input to their products; and whole genome sequencing on human samples for research projects, such as population sequencing initiatives. Its services are used by pharmaceutical companies for translational research, biomarker discovery, the development of personalized cancer therapies, and for clinical trials, as well as tests are used by physicians to detect residual or recurrent cancer in patients, monitor cancer response to therapy, and uncover insights for therapy selection. The company's customers include pharmaceutical companies, biopharmaceutical companies, diagnostics companies, universities, non-profits, government entities, and patients. The company has strategic collaboration with Tempus AI, Inc. to bring ultra-sensitive cancer recurrence testing to colorectal cancer patients. Personalis, Inc. was incorporated in 2011 and is headquartered in Fremont, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.